The Effect of Intravitreal Ranibizumab on the Fellow Untreated Eye with Subfoveal Scarring due to Exudative Age-Related Macular Degeneration
Explore this paper's citation graph
Summary
Ranibizumab might induce some therapeutic effect in selected cases of end-stage CNV scarring, which needs to be further examined and the VEGF levels in the compartments of the fellow eye of patients with age-related macular degeneration treated with ranibizUMab need to beFurther evaluated.
- Type
- article
- Published
- 2009-07-15
- Cited by
- 34
- References
- 26
- OpenAlex
- https://openalex.org/W19602910
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:2054134
Keywords
Derecho, Geography, Political science, Humanities, Philosophy
References
- Clinical Pharmacokinetics of Ranibizumab (LucentisTM) in Subjects With AMD
- Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor.
- Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes.
- Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen.
- Age-Related Macular Degeneration: Review of Pathogenesis
- Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes.
- Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis.
- Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy.
- Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastin) injections.
- Ranibizumab in neovascular age-related macular degeneration
- Pharmacokinetics of intravitreal ranibizumab (Lucentis).
- Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate.
- Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration
- Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
- Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.
- PHARMACOKINETICS AND RETINAL DISTRIBUTION OF RANIBIZUMAB, A HUMANIZED ANTIBODY FRAGMENT DIRECTED AGAINST VEGF-A, FOLLOWING INTRAVITREAL ADMINISTRATION IN RABBITS
- Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
- Pharmacokinetics of intravitreal bevacizumab (Avastin).
- The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975.
- Age-Related Macular Degeneration (AMD)
Cited by
- Effect of intravitreal dexamethasone implant on the contralateral eye: a case report.
- Development of Age-Related Macular Degeneration (AMD) in the Fellow Eye of Patients with AMD Treated by Treat-and-Extend Intravitreal Therapy with Aflibercept
- Different Effects of Ranibizumab and Bevacizumab on Platelet Activation Profile
- Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome
- Incidence of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation
- Comparison of the Effect of Unilateral Intravitreal Bevacizumab and Ranibizumab Injection on Diabetic Macular Edema of the Fellow Eye
- Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab
- The long-term effect of intravitreal ranibizumab on retinal nerve fiber layer thickness in exudative age-related macular degeneration
- BILATERAL EFFECT OF UNILATERAL RANIBIZUMAB IN PATIENTS WITH UVEITIS-RELATED MACULAR EDEMA
- Pegaptanib Sodium in the Treatment of Neovascular Age-Related Macular Degeneration
- Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
- Intravitreal Injection of Ranibizumab for Treatment of Age-Related Macular Degeneration: Effects on Serum VEGF Concentration
- INCIDENCE AND CHARACTERISTICS OF NEOVASCULARIZATION IN FELLOW EYES OF JAPANESE PATIENTS WITH UNILATERAL RETINAL ANGIOMATOUS PROLIFERATION
- Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration
- Effects of Intravitreal Injection of Bevacizumab or Ranibizumab on Systemic Circulation
- Intravitreal Anti-Vascular Endothelial Growth Factor Therapy and Retinal Nerve Fiber Layer Loss in Eyes With Age-Related Macular Degeneration: A Meta-Analysis.
- Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept.
- Assessment of Corneal Sensation, Innervation and Retinal Nerve Fiber Layer in Patients Treated with Multiple Intravitreal Ranibizumab Injections
- Intravitreal Bevacizumab Injection Therapy in a Case with Choroidal Neovascular Membrane Secondary to Toxoplasmosis Retinochoroiditis
- Comparative Retinal Vessel Size Study of Intravitreal Ranibizumab and Bevacizumab in Eyes with Neovascular Age-Related Macular Degeneration
Related papers
No related papers recorded.